Effect of vasoactive peptides on prostacyclin synthesis in man

• Published in: British journal of pharmacology Vol. 87; no. 1; pp. 243 - 247
• Main Authors: Barrow, Susan E., Dollery, Colin T., Heavey, Dennis J., Hickling, Nicola E., Ritter, James M., Vial, Janet
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.01.1986; Nature Publishing
• Subjects: 6-Ketoprostaglandin F1 alpha - blood; Adult; Angiotensin II - pharmacology; Arginine Vasopressin - pharmacology; Biological and medical sciences; Blood Pressure - drug effects; Bradykinin - pharmacology; Deamino Arginine Vasopressin - pharmacology; Epoprostenol - biosynthesis; Heart Rate - drug effects; Humans; Male; Medical sciences; Miscellaneous; Neuropharmacology; Pharmacology. Drug treatments; Human; Prostaglandin I2; 8-Arginine vasopressin; Arachidonic acid derivatives; Bradykinin; Hemodynamics; Angiotensin II; Biological activity
• ISSN: 0007-1188; 1476-5381
• DOI: 10.1111/j.1476-5381.1986.tb10177.x

1 Bradykinin, angiotensin II, arginine vasopressin (AVP) or des‐amino‐D‐arginine vasopressin (DDAVP) were administered by intravenous infusion to 10 healthy men. 2 The concentration of 6‐oxo‐prostaglandin F1α (6‐oxo‐PGF1α), the stable hydrolysis product of prostacyclin (PGI2), was measured in plasma using gas chromatography/negative ion chemical ionisation mass spectrometry. 3 Dose‐related increases in plasma concentrations of 6‐oxo‐PGF1α occurred during administration of bradykinin (100–3200 ng kg−1 min−1). The concentrations of 6‐oxo‐PGF1α rose from baseline values in the range < 1.0–4.9 pg ml−1 to 24.9–47.6 pg ml−1 at maximum tolerated infusion rates. 4 There were no changes in the concentrations of 6‐oxo‐PGF1α during administration of angiotensin II, AVP or DDAVP at infusion rates which caused haemodynamic changes.